2m 2m 2m 2m 2m 2m 2m
SAGIMET BIOSCN-A (SGMT)
NASDAQ
$6.91+$0.05 (+0.76%)
Price as of Jun 03, 2026 7:56 PM EDT- $446.0MMarket Cap
- 87.05%1-Year Change
- BiotechnologyIndustry
SAGIMET BIOSCN-A (SGMT)
$6.91+$0.05 (+0.76%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|
Income Statement | ||||
Total Operating Revenue | N/A N/A | 2.0M 0.00% | 2.0M N/A | |
Cost of Revenue | N/A N/A | N/A N/A | 0 N/A | |
Gross Profit | 0 -100.00% | 2.0M 0.00% | 2.0M N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -39.1M +1.59% | -38.4M +94.39% | -19.8M N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | N/A N/A | |
Total Operating Expenses | 56.9M +4.47% | 54.5M +66.32% | 32.7M N/A | |
Operating Profit | -56.9M +4.47% | -54.5M +77.14% | -30.7M N/A | |
Interest Income | 5.9M -34.16% | 8.9M +210.73% | 2.9M N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 5.9M -34.16% | 8.9M +210.73% | 2.9M N/A | |
Total Nonoperating Income and Expense | 5.9M -34.16% | 8.9M +210.30% | 2.9M N/A | |
Income before Taxes | -56.9M +4.47% | -54.5M +77.14% | -30.7M N/A | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -51.0M +12.01% | -45.6M +63.46% | -27.9M N/A | |
Net Income from Continuing Operations Applicable to Common | -51.0M +12.01% | -45.6M +63.46% | -27.9M N/A | |
Basic EPS and Net Income | -1.58 +8.97% | -1.45 -45.49% | -2.66 N/A | |
Diluted EPS and Net Income | -1.58 +8.97% | -1.45 -45.49% | -2.66 N/A | |
Basic Weighted Average Shares | 32.3M +3.17% | 31.4M +199.71% | 10.5M N/A | |
Diluted Weighted Average Shares | 32.3M +3.17% | 31.4M +199.71% | 10.5M N/A | |
Balance Sheet | ||||
Cash and Cash Equivalents | 35.0M -53.82% | 75.8M +0.93% | 75.1M N/A | |
Short-Term Investments | 78.1M +3.57% | 75.4M +281.67% | 19.8M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 113.1M -25.21% | 151.3M +59.38% | 94.9M N/A | |
Total Current Assets | 116.4M -23.81% | 152.8M +58.08% | 96.6M N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Assets | 0 -100.00% | 7.4M N/A | N/A N/A | |
Total Assets | 116.5M -27.32% | 160.3M +65.70% | 96.7M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 5.1M +14.53% | 4.5M -21.22% | 5.7M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 78,000 0.00% | 78,000 -4.88% | 82,000 N/A | |
Total Liabilities | 5.1M +14.53% | 4.5M -21.22% | 5.7M N/A | |
Retained Earnings | -346.3M +17.28% | -295.3M +18.25% | -249.7M N/A | |
Total Stockholders Equity | 111.4M -28.51% | 155.8M +71.09% | 91.1M N/A | |
Total Shares Outstanding | 567,494 N/A | 0 N/A | 0 N/A | |
Cash Flow | ||||
Cash from Operating Activities | -45.6M +7.58% | -42.4M +78.55% | -23.8M N/A | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | 4.6M +107.39% | -61.7M -590.33% | 12.6M N/A | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 275,000 -99.74% | 104.8M +21.65% | 86.2M N/A | |
Financials Ratio | ||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | -2,722.70% N/A | N/A N/A | |
Return on Assets | -36.88% +4.01% | -35.46% N/A | N/A N/A | |
Return on Equity | -38.20% +3.49% | -36.92% N/A | N/A N/A | |
Revenue Growth | N/A N/A | 0.00% N/A | N/A N/A | |
Current Ratio | 22.82 -33.47% | 34.30 N/A | N/A N/A | |
Cash Ratio | 6.87 -59.68% | 17.03 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow